PMCPA Case Analysis

Over 2,000 real rulings β€” analysed for what they mean to your team. Published every day.

All Cases PMCPA Case of the Week PMCPA Cases

Showing 1914 cases

2007
CASE
AUTH/2074/12/07 AstraZeneca

AstraZeneca rep left Symbicort sales literature during child’s GP appointment: breaches of Clauses 9.1 and 15.2 (AUTH/2074/12/07)

AstraZeneca representative used a private GP consultation (for his child) to leave Symbicort promotional material on the doctor’s desk. PMCPA ruled breaches…

2007
CASE
AUTH/2045/9/07 Novo Nordisk ⭐ Case of the Week

AUTH/2045/9/07: Lilly v Novo Nordisk – Levemir advertorial in Pulse and β€œweight advantages” claim

Lilly challenged a Levemir advertorial in Pulse. PMCPA found the β€œWeight advantages with Levemir” section misleading/ambiguous and inconsistent with the SPC. Breaches…

2007
CASE
AUTH/1993/4/07 AstraZeneca

AUTH/1993/4/07: Anonymous v AstraZeneca β€” alleged inappropriate hospitality (no breach)

Anonymous alleged AstraZeneca funded inappropriate hospitality at a Midlands Psychiatric Research Group meeting. Panel found the event primarily educational and no evidence…

2007
CASE
AUTH/1975/3/07 Allergan

AUTH/1975/3/07: Pfizer v Allergan β€” alleged Grand Canyon helicopter trip hospitality (No breach)

Pfizer alleged Allergan paid for UK ophthalmologists to take a Grand Canyon helicopter trip during AAO Las Vegas 2006. Panel found no…

2007
CASE
AUTH/1943/1/07 AstraZeneca

AstraZeneca meeting invitation implied SHA involvement (AUTH/1943/1/07)

A PCT prescribing lead said a statin strategy meeting invite implied it was run by the local SHA. Panel found the front…

AstraZeneca

AstraZeneca: call-frequency targets and incentives (AZpiration) found to risk overcalling (Casodex) β€” breaches of Clauses 9.1, 15.4 and 15.9

MHRA forwarded an ex-employee complaint alleging monthly call targets and prize-linked incentives encouraged overcalling. Panel ruled briefing materials advocated call rates likely…

2006
CASE
AUTH/1884/8/06 Servier Laboratories ⭐ Case of the Week

AUTH/1884/8/06: Hospital Chief Pharmacist v Servier (Protelos) – representative conduct, call frequency and inducements

Servier rep’s proactive call rate exceeded Code limits and biscuits/snacks were used to gain access. Panel found breaches of 15.3, 15.4 and…

2007
CASE
AUTH/2047/9/07 Janssen

AUTH/2047/9/07: PCT Director of Standards v Janssen-Cilag (Invega journal advertisement) – No breach

A PCT director alleged an Invega ad used unacceptable nudity/sexual imagery. PMCPA Panel found the image (woman shedding skin) was not used…

2017
CASE
AUTH/2985/10/17 Sun Pharma

Sun Pharma email promotion of ready-to-administer gemcitabine: risk-minimisation claim found misleading (AUTH/2985/10/17)

A pharmacist challenged Sun Pharma’s email claim that ready-to-administer gemcitabine β€œminimise[s] risk”. PMCPA found the claim misleading and unsubstantiated (Clauses 7.2, 7.4).…

2015
CASE
AUTH/2768/5/15 Roche Products

Roche: Clinical trial disclosure (Zelboraf) β€” outwith scope (AUTH/2768/5/15)

PMCPA Director complaint about clinical trial disclosure for Zelboraf. The matter was found outwith the scope of the ABPI Code (2015). No…

2018
CASE
AUTH/3019/2/18 Boehringer Ingelheim

AUTH/3019/2/18: Anonymous v Boehringer Ingelheim (Meeting advertised on LinkedIn) – No breach (out of scope)

Anonymous complaint about a meeting advertised on LinkedIn involving Boehringer Ingelheim. PMCPA concluded no breach and that the matter was outwith the…

2006
CASE
AUTH/1854/6/06 Servier Laboratories ⭐ Case of the Week

AUTH/1854/6/06: Servier – Coversyl journal ad alleged to breach an undertaking (no breach)

A pharmacist alleged Servier reused a Coversyl ad previously ruled misleading. The Panel found the ad had been revised to clarify combination…

2006
CASE
AUTH/1826/4/06 ProStrakan

ProStrakan press coverage of Rectogesic and SMC rejection: no breach (AUTH/1826/4/06)

A public complaint about a newspaper article quoting ProStrakan on Rectogesic’s indication and comparisons with surgery. Panel focused on what the company…

2007
CASE
AUTH/2034/8/07 Recordati Pharmaceuticals

AUTH/2034/8/07: MHRA v Recordati β€” Tradorec XL leavepiece and prohibited β€˜MHRA advice’ reference

Recordati’s Tradorec XL leavepiece quoted β€˜MHRA advice’ on prescribing prolonged-release tramadol by brand. The Panel ruled this breached Clause 9.5: MHRA references…

2007
CASE
AUTH/2014/6/07 Pfizer

AUTH/2014/6/07: Consultant in Public Health v Pfizer – Promotion of Champix (varenicline) (No breach)

A PCT public health consultant alleged Pfizer’s Champix promotion was premature (pre-NICE), undermined local guidelines/NRT, and bypassed the stop smoking service. The…

Ask questions about any PMCPA case

Anzal, our PMCPA rulings expert, has knowledge of over 2,000 published cases β€” ask about precedents, clauses, and how they apply to your situation.

⭐ Flagship Programme

AQP Flagship Path — the complete UK ABPI signatory programme

12 modules. 12 weeks. Final Signatory readiness. The industry standard for ABPI Code signatories — £995 + VAT.

Enrol — AQP Path Learn more

📰 Weekly PMCPA Case Breakdown

One real case. One key lesson. Every week β€” free.

Subscribe Free
🎓 AQP Training